Holen Sie sich die Stockscreener-App
8.94
1.97%
-0.18
Handel nachbörslich:
8.94
Schlusskurs vom Vortag:
$9.12
Offen:
$9.04
24-Stunden-Volumen:
818.56K
Relative Volume:
0.72
Marktkapitalisierung:
$873.55M
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-2.8932
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+8.36%
1M Leistung:
+30.13%
6M Leistung:
-41.53%
1J Leistung:
-43.06%
1-Tages-Spanne:
$8.775
$9.10
1-Wochen-Bereich:
$7.85
$9.35
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
8.94 | 873.55M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Long Term Trading Analysis for (RCUS) - news.stocktradersdaily.com
Wells Fargo & Company MN Has $575,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Taking the lead: Arcus Biosciences Inc (RCUS) - Sete News
Arcus Biosciences Inc (RCUS) Stock: Navigating a Year of Volatility - investchronicle.com
Can you now get a good deal on Arcus Biosciences Inc’s shares? - uspostnews.com
Arcus Biosciences Inc [RCUS] Investment Guide: What You Need to Know - knoxdaily.com
Arcus Biosciences Inc (NYSE: RCUS) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Invesco Ltd. - Defense World
Barclays Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $14.00 - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
RCUSArcus Bioscience Latest Stock News & Market Updates - Stock Titan
Are Arcus Biosciences Inc (RCUS) shares a good deal now? - uspostnews.com
Russell Investments Group Ltd. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences to Present First Combination Data for HIF-2a I - GuruFocus
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting | RCUS Stock News - GuruFocus
Groundbreaking Kidney Cancer Treatment Data: Arcus Reveals First Casdatifan-Cabozantinib Results at ASCO 2025 - Stock Titan
Arcus Biosciences Inc (RCUS) Is A Buy According To Analysts - Marketing Sentinel
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences - Benzinga
Arcus Biosciences (RCUS) Price Target Slashed by Barclays to $14 - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update | RCUS Stock News - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quart - GuruFocus
Geode Capital Management LLC Decreases Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
ARCUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain restricted stock units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Options of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Alliancebernstein L.P. - Defense World
Norges Bank Buys Shares of 34,044 Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Vanguard Group Inc. Sells 79,539 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Corebridge Financial Inc. Sells 2,258 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
American Century Companies Inc. Increases Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies - Investing.com Australia
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies By Investing.com - Investing.com South Africa
Arcus Biosciences' SWOT analysis: biotech stock's potential in cancer therapies - Investing.com
KLP Kapitalforvaltning AS Purchases Shares of 13,900 Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
RCUS stock touches 52-week low at $7.5 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $7.5 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
(RCUS) Trading Signals - news.stocktradersdaily.com
Institutional owners may consider drastic measures as Arcus Biosciences, Inc.'s (NYSE:RCUS) recent US$134m drop adds to long-term losses - simplywall.st
Arcus Biosciences patents new c-Kit inhibitors - BioWorld MedTech
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo
RCUS stock touches 52-week low at $8.81 amid market challenges - Investing.com
Cancer Therapy Pioneer Arcus Biosciences Accelerates Growth with Key Team Expansion - Stock Titan
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Amundi - Defense World
RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):